
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is positioned for positive revenue growth driven by its expanding oncology portfolio and strong performance in existing therapeutic areas, particularly HIV. The anticipated approval and launch of Trodelvy in the metastatic triple-negative breast cancer segment, along with a significant increase in payer coverage, highlight Gilead's commitment to diversifying its revenue streams. Additionally, projected sales growth from key products such as Livdelzi, along with continued strong performance in the HIV franchise and the PrEP market, underscores the company's operational efficiency and potential for sustained financial success moving forward.
Bears say
Gilead Sciences has experienced a significant reduction in projected revenues, notably lowering its FY25 Veklury revenue guidance from $1.4 billion to $1.0 billion, with a further decline anticipated for 2026, which is forecasted at $600 million. The company’s cell therapy franchise has shown a continuous revenue decline of 6% year-over-year, and a 10% decrease is expected in 2026, attributed to competitive pressures within the sector. Additionally, Gilead is facing policy-related headwinds and declining sales from its antiviral products, further suggesting a negative outlook for the company’s financial health moving forward.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares